Clinic
Saint Joseph Regional Medical Center-South Bend Campus, INC.
Saint Joseph Regional Medical Center-South Bend Campus, INC. was paid $18.69M by Medicaid between Jan 2018 and Nov 2024, across 102 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoSAINT JOSEPH REGIONAL MEDICAL CENTER-SOUTH BEND CAMPUS, INC.
MISHAWAKA, IN 46545
MISHAWAKA, IN 46545
33aNPI1841245594assigned 05/23/2006
33bProvider typeHearing and Speech Clinic/Center
28Total paid$18.69M
24GClaims342,766
24DCodes billed102
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Hearing and Speech Clinic/Center providers in Indiana
Rank by total paid#1 of 10
Median peer was paid$62K
This provider vs. median300×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KARAM, CHRISTOPHER controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,614 | $1.42M | |
| 2019 | 35,893 | $1.68M | |
| 2020 | 29,455 | $1.51M | |
| 2021 | 41,100 | $2.45M | |
| 2022 | 73,534 | $4.20M | |
| 2023 | 61,101 | $3.76M | |
| 2024incomplete | 55,069 | $3.68M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 38,521 | 33,944 | $5.31M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 29,420 | 25,539 | $4.32M |
| 71045 | Radiologic examination, chest; single view | 6.5% | 8,473 | 7,136 | $1.21M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.4% | 8,432 | 6,946 | $1.19M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.6% | 8,118 | 7,283 | $1.04M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.1% | 10,671 | 8,724 | $760K |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.0% | 371 | 337 | $754K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.2% | 6,432 | 5,415 | $594K |
| 71046 | Radiologic examination, chest; 2 views | 2.8% | 6,611 | 5,681 | $529K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.8% | 8,497 | 7,332 | $524K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 15,879 | 13,356 | $259K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 597 | 499 | $212K |
90 more codes
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.1% | 1,840 | $211K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 46,227 | $185K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 57 | $164K |
| 80053 | Comprehensive metabolic panel | <1% | 27,023 | $163K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,151 | $124K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 971 | $119K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,278 | $119K |
| 87631 | <1% | 1,243 | $115K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 41,835 | $96K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 428 | $79K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,816 | $54K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 154 | $52K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 401 | $38K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,026 | $37K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 375 | $36K |
| 81001 | <1% | 20,581 | $35K | |
| G0378 | Hospital observation service, per hour | <1% | 172 | $29K |
| 84484 | <1% | 3,258 | $27K | |
| 94060 | <1% | 416 | $27K | |
| 84703 | <1% | 4,567 | $24K | |
| 83690 | <1% | 6,502 | $23K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 428 | $21K |
| 73630 | <1% | 482 | $20K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 106 | $19K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 445 | $18K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 650 | $14K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 811 | $13K |
| 95819 | <1% | 29 | $11K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 231 | $11K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 501 | $10K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 109 | $10K |
| 83970 | <1% | 192 | $7K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 244 | $6K |
| 85027 | <1% | 1,086 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 194 | $4K |
| 84425 | <1% | 190 | $4K | |
| 93976 | <1% | 13 | $3K | |
| 83735 | <1% | 725 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 216 | $3K |
| 81025 | <1% | 799 | $3K | |
| 87807 | <1% | 204 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,764 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 315 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 93 | $3K |
| 82607 | <1% | 192 | $3K | |
| 80061 | Lipid panel | <1% | 214 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 70 | $2K |
| 71250 | <1% | 13 | $2K | |
| 83525 | <1% | 192 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 105 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 38 | $2K |
| 72100 | <1% | 31 | $2K | |
| 87536 | <1% | 51 | $2K | |
| 84439 | <1% | 191 | $2K | |
| 83550 | <1% | 190 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 204 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 55 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 55 | $1K |
| 87081 | <1% | 261 | $1K | |
| 85730 | <1% | 272 | $1K | |
| 83540 | <1% | 190 | $1K | |
| 83605 | <1% | 235 | $1K | |
| 85610 | <1% | 273 | $881.15 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 28 | $870.00 |
| 83880 | <1% | 27 | $614.90 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 170 | $550.86 |
| 86360 | <1% | 34 | $529.99 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 14 | $456.17 |
| 86359 | <1% | 34 | $425.62 | |
| 82248 | <1% | 117 | $398.47 | |
| 84550 | <1% | 100 | $392.07 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,287 | $391.04 |
| 94729 | <1% | 125 | $381.90 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,310 | $255.74 |
| 99000 | <1% | 137 | $201.64 | |
| 99001 | <1% | 81 | $59.28 | |
| 86850 | <1% | 12 | $39.08 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 209 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 190 | $0.00 |
| 94726 | 0% | 125 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 17 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 30 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 17 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 510 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 636 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 241 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 172 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 56 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 49 | $0.00 |
| 96376 | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKARAM, CHRISTOPHER (PRESIDENT)
Parent organizationTRINITY HEALTH CORPORATION
| Provider | Location | Paid |
|---|---|---|
| Saint Joseph Regional Medical Center, INC. | Mishawaka, IN | $10.66M |
| Saint Joseph Regional Medical Center- Plymouth Campus INC | Plymouth, IN | $6.48M |
| Saint Joseph Regional Medical Center, INC. | Plymouth, IN | $5.55M |
| Saint Joseph Regional Medical Center-South Bend Campus, INC. | Mishawaka, IN | $4.81M |
| Saint Joseph Regional Medical Center-South Bend Campus, INC. | South Bend, IN | $923K |
| Saint Joseph Regional Medical Center- Plymouth Campus INC | Plymouth, IN | $771K |
| Saint Joseph Regional Medical Center-South Bend Campus, INC | Mishawaka, IN | $374K |
| Saint Joseph Regional Medical Center-South Bend Campus, INC. | Mishawaka, IN | $10K |
| Saint Joseph Regional Medical Center- Plymouth Campus INC | Plymouth, IN | $9K |
| Orthocare Pain and Rehabilitation Medicine LLC | Maple Shade, NJ | $1K |
| Saint Joseph Regional Medical Center-South Bend Campus, INC. | South Bend, IN | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.